Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies.
作者信息
Devine Steven M, Horowitz Mary M
机构信息
National Marrow Donor Program/Be The Match, Minneapolis, MN.
Center for International Blood and Marrow Transplant Research, Minneapolis, MN.
出版信息
J Clin Oncol. 2021 Feb 10;39(5):534-544. doi: 10.1200/JCO.20.01623. Epub 2021 Jan 12.
Abstract
摘要
相似文献
1
Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies.构建适用于特定目的的临床试验基础设施，以加速新型造血细胞移植策略和细胞免疫疗法的评估。
J Clin Oncol. 2021 Feb 10;39(5):534-544. doi: 10.1200/JCO.20.01623. Epub 2021 Jan 12.
2
Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation.同种异体造血干细胞移植中的特异性过继细胞免疫治疗。
Oncol Res Treat. 2017;40(11):691-696. doi: 10.1159/000484051. Epub 2017 Oct 26.
3
Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.血液系统恶性肿瘤患者异基因造血干细胞移植后的过继性免疫治疗
Transfus Med Rev. 2015 Oct;29(4):259-67. doi: 10.1016/j.tmrv.2015.07.001. Epub 2015 Jul 10.
4
Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.同种异体免疫治疗以优化移植物抗肿瘤效应：概念和争议。
Expert Rev Hematol. 2010 Jun;3(3):301-14. doi: 10.1586/ehm.10.29.
5
Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation.自体和异基因造血干细胞移植后的细胞过继性免疫治疗。
Cancer Treat Res. 2009;144:497-537. doi: 10.1007/978-0-387-78580-6_20.
6
Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis.定义细胞治疗的成功：临床终点和毒性分析的当前格局。
Blood. 2018 Jun 14;131(24):2630-2639. doi: 10.1182/blood-2018-02-785881. Epub 2018 May 4.
7
One size does not fit all: personalized immune therapies poised to take center stage.一刀切并不适用于所有人：个性化免疫疗法即将成为焦点。
J Natl Cancer Inst. 2013 May 1;105(9):583-4. doi: 10.1093/jnci/djt103. Epub 2013 Apr 16.
8
Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials.基于自然杀伤细胞的癌症免疫疗法：对已完成的10年临床试验的综述
Cancer Invest. 2018;36(8):431-457. doi: 10.1080/07357907.2018.1515315. Epub 2018 Oct 16.
9
The roles of stem cell memory T cells in hematological malignancies.干细胞记忆性T细胞在血液系统恶性肿瘤中的作用。
J Hematol Oncol. 2015 Oct 14;8:113. doi: 10.1186/s13045-015-0214-5.
10
Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies.明确供体淋巴细胞输注在高危血液系统恶性肿瘤中的作用
J Clin Oncol. 2021 Feb 10;39(5):397-418. doi: 10.1200/JCO.20.01719. Epub 2021 Jan 12.
引用本文的文献
1
The quest for the holy grail: overcoming challenges in expanding human hematopoietic stem cells for clinical use.对圣杯的追求：克服在扩大人类造血干细胞以供临床使用方面的挑战。
Stem Cell Investig. 2023 Jul 11;10:15. doi: 10.21037/sci-2023-016. eCollection 2023.
2
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?我们如何将新证据更好地转化到造血细胞移植和细胞治疗的实践中？
Blood Rev. 2023 Jul;60:101079. doi: 10.1016/j.blre.2023.101079. Epub 2023 Apr 7.
3
Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice.我们在预防移植物抗宿主病和改善临床结局方面取得进展了吗？BMT CTN 1301 研究结果对临床实践的影响。
Transplant Cell Ther. 2022 Aug;28(8):419-425. doi: 10.1016/j.jtct.2022.05.002. Epub 2022 May 9.
4
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.血液和骨髓移植临床研究网络 2021 年科学研讨会：展望未来，网络迎来成立 20 周年。
Transplant Cell Ther. 2021 Nov;27(11):885-907. doi: 10.1016/j.jtct.2021.08.016. Epub 2021 Aug 27.
本文引用的文献
1
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States.美国造血细胞移植的当前使用情况及趋势
Biol Blood Marrow Transplant. 2020 Aug;26(8):e177-e182. doi: 10.1016/j.bbmt.2020.04.013. Epub 2020 May 11.
2
Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey.COVID-19 对肿瘤学临床试验开展的早期影响及长期变革机遇：美国临床肿瘤学会调查研究结果。
JCO Oncol Pract. 2020 Jul;16(7):417-421. doi: 10.1200/OP.20.00275. Epub 2020 May 12.
3
The Emerging Landscape of Immune Cell Therapies.免疫细胞疗法的新兴领域。
Cell. 2020 Apr 2;181(1):46-62. doi: 10.1016/j.cell.2020.03.001.
4
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.KTE-X19 嵌合抗原受体 T 细胞疗法治疗复发或难治性套细胞淋巴瘤。
N Engl J Med. 2020 Apr 2;382(14):1331-1342. doi: 10.1056/NEJMoa1914347.
5
Telemedicine 2020 and the next decade.2020年及未来十年的远程医疗。
Lancet. 2020 Mar 14;395(10227):859. doi: 10.1016/S0140-6736(20)30424-4.
6
Virtually Perfect? Telemedicine for Covid-19.近乎完美？用于新冠疫情的远程医疗
N Engl J Med. 2020 Apr 30;382(18):1679-1681. doi: 10.1056/NEJMp2003539. Epub 2020 Mar 11.
7
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.嵌合抗原受体修饰的自然杀伤细胞在 CD19 阳性淋巴肿瘤中的应用。
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
8
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.临床肿瘤学进展 2020：美国临床肿瘤学会癌症进展年度报告。
J Clin Oncol. 2020 Apr 1;38(10):1081. doi: 10.1200/JCO.19.03141. Epub 2020 Feb 4.
9
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.抗 CD19 CAR T 细胞在 B 细胞淋巴瘤患者中具有完全人源结合结构域的安全性和可行性。
Nat Med. 2020 Feb;26(2):270-280. doi: 10.1038/s41591-019-0737-3. Epub 2020 Jan 20.
10
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
Zotero 插件